Trials / Completed
CompletedNCT02207062
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University of Washington · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot phase II trial studies ibrutinib in treating patients with transformed indolent (a type of cancer that grows slowly) B-cell non-Hodgkin lymphoma that have returned after a period of improvement (relapsed) or do not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes (proteins) needed for cell growth.
Detailed description
OUTLINE: Patients receive ibrutinib orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for up to 5 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib | Given PO |
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
- First posted
- 2014-08-01
- Last updated
- 2025-01-07
- Results posted
- 2025-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02207062. Inclusion in this directory is not an endorsement.